Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective multi-center real-world study of 90 RRMM pts txd w/ BCMA-directed CAR-T finds EMD/PCL dominant determinant of outcome (adjusted HR 4.85), outweighs bridging impact, though talq associated w/ favorable PFS.”
Title: Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Authors: Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler-Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer-Ausch, Sigrid Machherndl-Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Maria-Theresa Krauth
You can read the Full Article on Transplantation and Cellular Therapy.
You can find other articles featuring Robert Orlowski on OncoDaily.
